Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.

    Benjamin Rains headshot

    3 Stocks to Buy Ahead of Earnings

    Stocks opened higher on Monday as investors seem to think the U.S.-led air strikes on Syria won't lead to a much larger conflict. The strikes also coincided with the real start of first quarter earnings season, which investors should use as a way to fight off the volatility that has plagued markets recently.

      Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

      Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.

        Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?

        Intuitive Surgical's (ISRG) developments on the da Vinci platform are a positive, while intense competition raises concern.

          Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?

          Abbott (ABT) poised to gain on continued growth in Medical devices business in Q1.

            Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?

            Abbott (ABT) poised to ride high on strength in EPD business in Q1.

              Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?

              Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.

                Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?

                Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.

                  Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device

                  Abbott (ABT) adopts ways to strengthen Heart Failure business under the Medical Device segment.

                    Urmimala Biswas headshot

                    Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire

                    Chances of a retaliation from China leads to widespread losses in the medical device sector.

                      Edwards (EW) Completes Enrollment for PARTNER 3 Sub-Study

                      Edwards' (EW) near-term product pipeline looks quite encouraging.

                        Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK

                        Baxter (BAX) steadily focuses on improving its Advanced Surgery business.

                          Sweta Jaiswal headshot

                          Can Boston Scientific's Pain be a Boon for Edwards & Others?

                          Boston Scientific delaying the re-introduction of Lotus Valve devices provides an edge to its competitors in the highly lucrative TAVR market.

                            Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLW

                            Abbott (ABT) is is leaving no stone unturned to drive its Structural Heart business.

                              Urmimala Biswas headshot

                              Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus

                              According to Goldman Sachs, emerging markets are world's best investment in spite of several external hiccups. This comes as a breather for MedTech investors keen on exposure to emerging markets.

                                Sweta Jaiswal headshot

                                Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

                                Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

                                  Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?

                                  Big pharma companies are using their savings in tax to boost shareholders' wealth through dividends or share buybacks, ignoring consumers.

                                    Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio

                                    Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.

                                      Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

                                      Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific

                                        Abbott to Strengthen Vascular Care Arm With Surmodics Deal

                                        Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.

                                          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

                                          Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific

                                            Abbott (ABT) Down 6.7% Since Earnings Report: Can It Rebound?

                                            Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

                                              FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

                                                Cardiovascular Systems Portfolio Solid, Competition Rife

                                                Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.

                                                  Abbott's FreeStyle LibreLink App Now Available in Europe

                                                  Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.